Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Faricimab by F. Hoffmann-La Roche for Non-Proliferative Diabetic Retinopathy (NPDR): Likelihood of Approval
Faricimab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According...
Data Insights
Faricimab by F. Hoffmann-La Roche for Choroidal Neovascularization: Likelihood of Approval
Faricimab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Choroidal Neovascularization. According to GlobalData,...